Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Myeloma in 2020

Graham Jackson • 16 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies CAR-T Daratumumab

Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, outlines the ever-evolving treatment landscape of myeloma treatment. Specifically discussed is the use of daratumumab, anti-BCMA strategies and the use of quadruplet regimens. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Graham Jackson

0:58
Education gaps in CAR-T therapy
Graham Jackson • 13 May 2022
0:58
The efficacy of ixazomib for the treatment of R/R myeloma
Graham Jackson • 13 May 2022
1:09
Treatment holidays in multiple myeloma
Graham Jackson • 13 May 2022
1:10
Infection prophylaxis in multiple myeloma
Graham Jackson • 13 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals